Document is current
Any future updates will be listed below
-
Authors
Ryan, Christine E. https://orcid.org/0000-0003-2588-1943
Ahn, Inhye E.
Sekar, Aswin
Rawstron, Andrew
Almeida, Julia https://orcid.org/0000-0003-3124-8917
Martin-Subero, IƱaki https://orcid.org/0000-0001-8809-5195
Parry, Erin M.
Alcoceba, Miguel
Calado, Dinis P.
Orfao, Alberto https://orcid.org/0000-0002-0007-7230
Langerak, Anton W. https://orcid.org/0000-0002-2078-3220
Veelken, Hendrik https://orcid.org/0000-0002-9108-3125
Langerbeins, Petra
Stephens, Deborah M.
Parikh, Sameer A. https://orcid.org/0000-0002-3221-7314
Niemann, Carsten U. https://orcid.org/0000-0001-9880-5242
Roulland, Sandrine
Stamatopoulos, Kostas https://orcid.org/0000-0001-8529-640X
Slager, Susan L. https://orcid.org/0000-0002-5173-4712
Shanafelt, Tait
Ghia, Paolo https://orcid.org/0000-0003-3750-7342
Okosun, Jessica https://orcid.org/0000-0001-6021-5044
Davids, Matthew S. https://orcid.org/0000-0003-4529-2003
- License Information
-
More Information
Article History
Received: 9 March 2025
Revised: 30 June 2025
Accepted: 28 July 2025
First Online: 29 August 2025
Competing interests
: CER has received consulting fees from AstraZeneca and Genentech, and has received institutional research funding from BeiGene, Genentech, and Lilly. IEA has received consulting fees from AstraZeneca, BeiGene, and Lilly, and institutional research funding from BeiGene and Lilly. MA has received research funding from Gilead. AO has received institutional research support from BluePrint Medicines and institutional consultancy fees from Becton/Dickinson Biosciences and BluePrint Medicines; he has also been a speaker for Amgen, Becton/Dickinson Biosciences and AstraZeneca. AWL has received research funding from Roche-Genentech and Janssen. PL has received honoraria and personal fees from AbbVie, AstraZeneca, BeiGene, Janssen and has received research funding from Janssen. DMS has received consulting fees from Abbvie, AstraZeneca, Beigene, Genentech, Janssen, and Pharmacyclics, and has received institutional research funding from Abbvie, AstraZeneca, Beigene, BMS, and Novartis. CUN has received research funding and/or consultancy fees from Abbvie, AstraZeneca, Janssen, BeiGene, Genmab, Octapharma, Takeda, CSL Behring, MSD, Lilly. SR has received research fundings from Bristol Myers Squibb. KS has received research support from AbbVie, AstraZeneca, Janssen, Lilly and Novartis. TS has received research support from AbbVie, Genentech, and Pharmacyclics. PG has received research funding from AbbVie, AstraZeneca, BeiGene, BMS, Janssen, Lilly and MSD and has received honoraria from AbbVie, AstraZeneca, BeiGene, BMS, Galapagos, Janssen, MSD, Roche. JO has received consulting fees from AstraZeneca, BeiGene, Eisai, Genmab and Incyte and has received research funding from AstraZeneca, BeiGene and Genmab. MSD has received consulting fees from AbbVie, Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Bristol Myers Squibb, Galapagos, Genentech, Genmab, Janssen, Merck, MEI Pharma, Nuvalent, and SchrÓ§dinger; has received institutional research funding from Ascentage Pharma, MEI Pharma, and Novartis, and receives royalties from Up-To-Date. AS, AR, JA, IMS, EMP, DPC, HV, SP, and SLS declare no relevant disclosures.
